Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Malignant pleural effusion
Respiratory · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Time-critical presentation
Severe breathlessness, hypoxaemia, haemodynamic compromise or mediastinal shift from a large effusion requires urgent senior respiratory assessment and monitored image-guided drainage. Drain in a controlled manner and stop for chest pain, persistent cough or physiological deterioration; do not perform a blind emergency aspiration unless no safer lifesaving option exists.
Overview
Diagnose malignant pleural effusion efficiently and choose symptom-led definitive drainage that respects lung expandability, prognosis, cancer treatment, home support and patient preference.
Malignant fluid forms through pleural tumour, lymphatic obstruction, vascular permeability and sometimes concurrent cardiac, hepatic, renal or thromboembolic disease. A patient with cancer can therefore have a paramalignant effusion that is not cytology-positive, and a new unilateral effusion should not be assumed malignant without assessment.
The diagnostic and therapeutic plans should be integrated. If imaging shows a safe fluid pocket, ultrasound-guided aspiration can provide cytology and test symptom response. If cytology is negative but suspicion persists, image-guided pleural biopsy or thoracoscopy usually has higher yield; repeating aspiration is useful only when the expected incremental value and molecular needs justify it.
Definitive management is preference-sensitive. Talc pleurodesis aims to fuse pleural surfaces and generally needs an expandable lung and a drain or thoracoscopy. An indwelling pleural catheter enables outpatient intermittent drainage and works with trapped lung but requires community support and carries blockage, cellulitis and infection risks. Current BTS guidance should be paired with the local pleural MDT and cancer pathway.
Key points
Aetiology
01
Metastatic carcinoma
Lung, breast, ovarian and other cancers spread to pleura or obstruct mediastinal lymphatics, accounting for many malignant effusions.
02
Pleural mesothelioma
Diffuse primary pleural tumour produces recurrent exudative fluid, pleural thickening and later lung encasement, especially when other respiratory vulnerabilities are present.
03
Haematological malignancy
Lymphoma and leukaemia may involve pleura, block lymphatic drainage or occasionally produce a chylous malignant collection.
04
Cancer-treatment effects
Radiotherapy, surgery, infection, embolism and cardiac or renal toxicity can cause a non-malignant effusion in someone who also has cancer.
Pathophysiology
1
Pleural tumour involvement
Malignant cells implant on pleural surfaces and increase capillary permeability through inflammatory and growth mediators, which links the underlying lesion to the observed respiratory dysfunction.
2
Lymphatic obstruction
Tumour blocks stomata, channels or mediastinal nodes that normally remove pleural fluid, thereby altering ventilation, gas transfer or respiratory mechanics.
3
Fluid accumulation
Production exceeds clearance, creating a recurrent exudate that compresses adjacent lung and causes breathlessness, and the downstream physiological effect determines clinical severity.
4
Loss of lung expandability
Visceral pleural restriction or endobronchial obstruction can prevent re-expansion after drainage, producing trapped or non-expandable lung.
Clinical features and red flags
Symptomatic recurrent effusion
Progressive breathlessness, chest heaviness, reduced movement and stony dullness with reaccumulating unilateral fluid is the common presentation; functional response to drainage helps confirm causality.
Pleural malignancy imaging
Nodular or circumferential pleural thickening, mediastinal pleural involvement, fissural nodules, chest-wall invasion or an unexplained unilateral effusion raises suspicion and informs biopsy route.
Non-expandable lung
Persistent dyspnoea, hydropneumothorax, pain during drainage or failure of the lung to appose the chest wall suggests visceral pleural restriction or proximal airway obstruction and makes pleurodesis less likely to work.
Tension physiology or rapid compromiseRed flag
Severe distress, hypoxaemia, hypotension or major mediastinal displacement from a large effusion requires urgent monitored drainage and simultaneous assessment for other causes.
Pleural infection during cancer careRed flag
Fever, pleuritic pain, neutrophilic fluid, low pH, purulence or an infected catheter requires prompt antibiotics and pleural-team review rather than attribution to malignancy alone.
Investigations
01Thoracic ultrasoundFirst step
Why
Confirm fluid, septation, pleural abnormality and a safe intervention site.
Interpretation and limitations
A small, loculated or inaccessible pocket changes risk. Ultrasound can identify pleural nodularity but cannot establish malignancy; all aspirations and drains should be image guided.
Time CT relative to drainage with the pleural team; a completely compressed lung can hide lesions, while prior drainage may improve assessment. Negative CT does not exclude microscopic pleural malignancy.
03Ultrasound-guided pleural aspiration
Why
Relieve symptoms, assess lung expansion and obtain diagnostic fluid.
Interpretation and limitations
Send cytology with cell block and communicate suspected tumour and required molecular tests. Also send protein, LDH, glucose, pH and microbiology when competing diagnoses are possible.
04Paired serum and pleural protein and LDH
Why
Classify the effusion and identify a discordant alternative mechanism.
Interpretation and limitations
Most malignant effusions are exudates, but diuresed cardiac fluid may be misclassified and a transudate does not absolutely exclude malignancy. Use the whole context.
Differential diagnosis
01
Paramalignant effusion
Cancer-associated embolism, infection, hypoalbuminaemia or heart failure may cause fluid without pleural malignant cells; the distinction affects staging and management.
02
Pleural infection
Fever, loculation, purulence, low pleural pH or positive microbiology supports empyema and changes the urgency of drainage.
03
Heart failure
Bilateral fluid, congestion and response to volume management favour a transudative cardiac mechanism, though diuresis may alter biochemical classification.
04
Tuberculous pleuritis
Lymphocyte-predominant exudate, epidemiological risk and granulomatous pleural tissue prompt mycobacterial culture rather than a malignancy assumption.
05
Benign asbestos pleural effusion
Prior asbestos exposure can cause a diagnosis-of-exclusion effusion, but occult mesothelioma requires careful imaging and follow-up.
Additional chapter-specific clues
Alternative cancer emergencyRed flag
Sudden pleuritic pain, haemoptysis, stridor, unilateral leg swelling or neurological deficit may indicate pulmonary embolism, central-airway obstruction or metastatic complication rather than fluid burden.
Management
01DiagnosisOne coordinated pleural-cancer pathwayFirst stepA new unilateral effusion is suspicious for malignancy.+
1AlternativeUse thoracic ultrasound and contrast-enhanced CT to define fluid, pleural targets, primary cancer and alternative causes.
2Perform image-guided aspiration when safe, sending an adequate cytology and cell-block sample plus tests for competing infection or transudative disease.
3If cytology is nondiagnostic and suspicion remains, move to image-guided biopsy or thoracoscopy rather than serial low-yield aspirations.
4Coordinate respiratory, pathology, radiology and oncology plans so tissue meets histological and molecular treatment needs.
02First drainageTest symptom response and lung expansionThe effusion is causing clinically important breathlessness.+
Complications
01
Recurrent breathlessness
Fluid commonly reaccumulates after simple aspiration, repeatedly compressing lung and disrupting activity or sleep, and increasing the burden of otherwise local respiratory disease.
02
Trapped lung
A visceral tumour rind or proximal obstruction prevents expansion, causing persistent space and limiting successful pleurodesis.
03
Loculation
Inflammation, previous procedures or infection can divide fluid into pockets and make symptom-relieving drainage incomplete, particularly when baseline cardiopulmonary reserve is limited.
04
Pleural infection
Indwelling devices and repeated access carry infection risk, which may cause empyema and interrupt cancer therapy.
05
Procedure-related harm
Drainage can cause pneumothorax, bleeding, pain or re-expansion injury, particularly when lung expandability is uncertain, with severity determined by its extent and the patient's underlying reserve.
Monitoring and follow-up
During drainage monitor breathlessness, chest pain, cough, oxygen saturation, pulse and blood pressure, stopping when symptoms or physiology become concerning.
After intervention confirm drain or IPC position, lung expansion and complications using the local imaging pathway and clinical findings.
Track recurrence by symptoms and ultrasound rather than scheduling repeated chest radiographs without a clinical question.
For IPC care, record drainage volume and tolerance, catheter function, exit-site appearance, fever and community support or supply problems.
Review cancer diagnosis, molecular results, performance status, treatment response and prognosis jointly with oncology and palliative care.
Reassess breathlessness after apparently successful fluid control for PE, anaemia, airway obstruction, lymphangitic disease, infection or heart failure.
Special situations
Drainage is a diagnostic trial
If substantial fluid removal produces little symptomatic benefit, repeated or definitive pleural procedures may add burden without addressing the actual cause of breathlessness.
Cytology yield is tumour-dependent
A negative result is less reassuring for mesothelioma and some other tumours. Choose tissue biopsy early when imaging and exposure history make those diagnoses likely.
Trapped lung changes the endpoint
The goal becomes symptom relief without forcing pleural apposition. Pneumothorax ex vacuo after drainage is often evidence of restriction rather than a procedural air leak needing suction.
IPC and pleurodesis are not a hierarchy
With expandable lung, both are reasonable. Hospital days, home drainage, recurrence tolerance and patient priorities may matter more than a small difference in efficacy.
Pleural and oncology plans should meet
Biopsy route, specimen handling and timing should anticipate molecular tests and systemic treatment so the patient does not undergo avoidable repeat procedures.
Common pitfalls
01
Assuming any effusion in a patient with cancer is malignant.
02
Repeating negative cytology indefinitely instead of obtaining pleural tissue.
03
Performing fluid procedures without thoracic ultrasound.
Delaying symptom control until anticancer therapy has had time to work.
06
Treating pneumothorax ex vacuo with aggressive suction without pleural review.
07
Ignoring home support, dexterity and patient preference when selecting an IPC.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
RespiratoryOriginal SBA
Recurrent effusion with non-expandable lung
A patient with metastatic cancer has recurrent symptomatic pleural fluid. Therapeutic aspiration relieves breathlessness, but the lung does not re-expand and pneumothorax ex vacuo is seen. Which definitive option is usually most appropriate?
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
A malignant pleural effusion usually indicates advanced cancer but prognosis and treatment options vary greatly by tumour type, molecular target, performance status and response to systemic therapy.
Breathlessness is the main treatment indication. Effusion size alone does not prove that fluid is the cause, especially with embolism, lymphangitic disease, airway obstruction or cardiac comorbidity.
Use thoracic ultrasound for every fluid procedure and obtain contrast-enhanced staging CT at the appropriate point in the diagnostic pathway.
Pleural-fluid cytology is a first diagnostic test for many suspected malignancies, but sensitivity varies; negative cytology does not exclude pleural cancer, particularly mesothelioma.
Plan specimen volume, cell block, immunocytochemistry and molecular requirements with pathology rather than repeatedly sending low-value small samples.
A therapeutic aspiration can show whether breathlessness improves and whether the lung expands, helping choose definitive treatment.
For recurrent symptomatic effusion with expandable lung, offer a choice between indwelling pleural catheter and talc pleurodesis, explaining hospital time, home drainage, recurrence and adverse effects.
An indwelling pleural catheter is usually preferred when lung is non-expandable or pleurodesis has failed; drainage frequency can be tailored to symptom control or a goal of autopleurodesis.
Do not defer definitive pleural control solely to wait for systemic anticancer treatment when the patient remains symptomatic.
Early palliative-care involvement complements active oncology by addressing breathlessness, anxiety, function and advance care needs.
05Pleural biopsy or medical thoracoscopy
Why
Obtain tissue after nondiagnostic cytology or when mesothelioma or actionable tumour profiling is likely.
Interpretation and limitations
Choose image-guided biopsy for a visible target and thoracoscopy when direct inspection, larger tissue or simultaneous pleurodesis is advantageous. Avoid poorly planned tracks in suspected mesothelioma.
Pneumothorax ex vacuo reflects non-expandable lung and is not managed like an enlarging iatrogenic tension pneumothorax. Correlate imaging with symptoms and air leak.
1
Explain that drainage may not relieve symptoms if lung, airway, embolic or cardiac disease is dominant.
2Perform controlled ultrasound-guided therapeutic aspiration with observations and stop for pain, persistent cough or deterioration according to the BTS procedure statement.
3Review symptom change and imaging for re-expansion, trapped lung and complications.
4DefinitiveUse the result, expected recurrence and patient goals to choose a definitive rather than repeatedly temporary strategy.
03Definitive controlChoose IPC or pleurodesis with the patientDefinitiveA symptomatic malignant effusion is recurrent or predictably likely to recur.+
1Assess lung expandability, prognosis, performance status, home and carer support, hospital preference and the oncology timeline.
2First lineWith expandable lung, explain indwelling catheter and talc pleurodesis as valid first-line choices with different burdens and outcomes.
3With non-expandable lung or failed pleurodesis, favour an indwelling catheter or intermittent aspiration when an invasive device is not appropriate.
4Agree drainage frequency, community supply, contact routes and a plan for infection, blockage, loculation or spontaneous pleurodesis.
04ComplicationManage catheter or pleurodesis problemsPain, fever, erythema, poor drainage, worsening dyspnoea or new air after intervention.+
1Use ultrasound and examination to distinguish blockage, loculation, infection, non-expandable lung and pneumothorax.
2Culture fluid and give antibiotics for suspected infection; many IPC infections can be treated while the catheter remains if drainage is effective.
3Discuss fibrinolytic use, catheter replacement or surgery only through the pleural team because evidence and bleeding risk vary.
4EscalationEscalate haemodynamic compromise, rapidly enlarging pneumothorax or major haemorrhage immediately.
Key medicines and prescribing safety4 treatments · regimens, roles and cautions+
Permits humane aspiration, drain, catheter, biopsy or thoracoscopy while maintaining patient cooperation.
Local anaesthetic for pleural intervention
Use the locally approved lidocaine regimen after weight, allergy, liver and cardiac review, documenting the total dose across skin, tract and pleura.
Pleural procedures can require substantial infiltration; calculate the cumulative dose and recognise tinnitus, circumoral symptoms, seizures or arrhythmia as toxicity.
Controls malignant pleuritic pain and procedure-related discomfort, improving ventilation and mobility.
Analgesia for pleural pain
Use regular non-opioid treatment with carefully titrated rescue analgesia according to renal function, bleeding risk, frailty and the current BNF.
NSAIDs may be unsuitable with renal disease or anticoagulation; opioids can cause sedation and respiratory depression. Pain during drainage can signal non-expandable lung and should not simply be suppressed.
Produces pleural symphysis to reduce recurrent malignant fluid after slurry or poudrage delivery.
Sterile graded talc for pleurodesis
Administer only through a trained pleural service using the current BTS and local protocol after confirming an appropriate expandable-lung strategy.
Requires informed comparison with IPC. Fever, pain, failed pleurodesis and rare respiratory complications can occur; do not use ungraded talc or proceed when pleural apposition is inadequate.
Treats the underlying cancer and may reduce effusion recurrence in responsive tumours.
Systemic anticancer therapy
Use tumour-specific oncology regimens based on histology, molecular results, performance status and the current NICE or national cancer pathway.
Do not delay needed symptom-directed pleural intervention while waiting for response. Check cytopenia, infection and procedural timing with oncology.